Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Equivalents (2016 - 2025)

Fortress Biotech has reported Cash & Equivalents over the past 13 years, most recently at $79.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $79.4 million for Q4 2025, up 38.63% from a year ago — trailing twelve months through Dec 2025 was $79.4 million (up 38.63% YoY), and the annual figure for FY2025 was $79.4 million, up 38.63%.
  • Cash & Equivalents for Q4 2025 was $79.4 million at Fortress Biotech, down from $86.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for FBIO hit a ceiling of $305.7 million in Q4 2021 and a floor of $57.3 million in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $88.8 million (2025), compared with a mean of $151.9 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 2500.44% in 2021 and later plummeted 68.64% in 2023.
  • Fortress Biotech's Cash & Equivalents stood at $305.7 million in 2021, then crashed by 41.69% to $178.3 million in 2022, then crashed by 54.6% to $80.9 million in 2023, then dropped by 29.24% to $57.3 million in 2024, then surged by 38.63% to $79.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $79.4 million (Q4 2025), $86.2 million (Q3 2025), and $74.4 million (Q2 2025) per Business Quant data.